Open Access

let‑7 and miR‑17 promote self‑renewal and drive gefitinib resistance in non‑small cell lung cancer

  • Authors:
    • Jun Yin
    • Weimin Hu
    • Lei Pan
    • Wenfan Fu
    • Lu Dai
    • Zeyong Jiang
    • Feng Zhang
    • Jian Zhao
  • View Affiliations

  • Published online on: June 12, 2019     https://doi.org/10.3892/or.2019.7197
  • Pages: 495-508
  • Copyright: © Yin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Epidermal growth factor receptor‑tyrosinase kinase inhibitor (EGFR‑TKI) resistance represents a major obstacle in the therapy of non‑small cell lung cancer (NSCLC), and the underlying molecular mechanisms are unknown. In this study, it was found that let‑7 family expression was downregulated and miR‑17 family expression was upregulated in gefitinib‑resistant PC9/GR cells compared with gefitinib‑sensitive PC9 cells. The downregulation of let‑7 and upregulation of miR‑17 have significant clinical relevance to gefitinib resistance in NSCLC. Moreover, it was shown that downregulation of let‑7 and upregulation of miR‑17 promoted resistance to gefitinib by regulating the self‑renewal capability of NSCLC cells. In addition, let‑7 participated in the maintenance of stem cell characteristics by regulating the target gene MYC, and miR‑17 participated in regulation of the cell cycle by regulating the target gene CDKN1A. In NSCLC cells, low expression of let‑7 increased MYC expression to help maintain the undifferentiated status, and high expression of miR‑17 decreased CDKN1A expression to help maintain the proliferative potential. Thus, both let‑7 and miR‑17 promoted self‑renewal, which is typical of stem cell‑like characteristics and resulted in gefitinib resistance. Therefore, this study demonstrated that let‑7 and miR‑17 were involved in the regulation of EGFR‑TKI resistance, and could be used as predictive biomarkers of EGFR‑TKI resistance in NSCLC.
View Figures
View References

Related Articles

Journal Cover

August 2019
Volume 42 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Yin, J., Hu, W., Pan, L., Fu, W., Dai, L., Jiang, Z. ... Zhao, J. (2019). let‑7 and miR‑17 promote self‑renewal and drive gefitinib resistance in non‑small cell lung cancer . Oncology Reports, 42, 495-508. https://doi.org/10.3892/or.2019.7197
MLA
Yin, J., Hu, W., Pan, L., Fu, W., Dai, L., Jiang, Z., Zhang, F., Zhao, J."let‑7 and miR‑17 promote self‑renewal and drive gefitinib resistance in non‑small cell lung cancer ". Oncology Reports 42.2 (2019): 495-508.
Chicago
Yin, J., Hu, W., Pan, L., Fu, W., Dai, L., Jiang, Z., Zhang, F., Zhao, J."let‑7 and miR‑17 promote self‑renewal and drive gefitinib resistance in non‑small cell lung cancer ". Oncology Reports 42, no. 2 (2019): 495-508. https://doi.org/10.3892/or.2019.7197